2024-09-15 - Analysis Report
##  ABBV Stock Analysis: A Detailed Look

This report offers a comprehensive analysis of AbbVie Inc. (ABBV), a pharmaceutical company known for its diverse portfolio of treatments across various therapeutic areas, including immunology, oncology, and neurology.

**1. Performance Comparison:**

* **ABBV's Cumulative Return:** 103.41%
* **S&P 500 (VOO) Cumulative Return:** 87.74%
* **Performance Gap:** ABBV has outperformed the S&P 500 by **15.67%**. This places ABBV's performance at **64.35%** relative to the historical performance range of the S&P 500, indicating that ABBV has outperformed the market over the considered period.

**2. Recent Price Movements:**

* **Closing Price:** $194.02
* **5-day Moving Average:** $195.56
* **20-day Moving Average:** $195.82
* **60-day Moving Average:** $183.12
* **Analysis:** ABBV is currently trading slightly below its 5-day and 20-day moving averages, indicating a potential short-term downward trend. However, the 60-day moving average suggests that ABBV has been on an upward trend in the longer term.

**3. Technical Indicators:**

* **RSI:** 44.83
* **PPO:** -0.47
* **Delta_Previous_Relative_Divergence:** -4.72 (Short-term downward trend)
* **Expected Return:** 16.87% (Estimated maximum 5-year expected return)
* **Analysis:** The RSI indicates that ABBV is currently in neutral territory, neither overbought nor oversold. The negative PPO suggests a potential slowdown in price momentum. The negative delta in relative divergence further reinforces the short-term downward trend indicated by the moving averages. However, the high expected return might be a positive factor for long-term investors.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

* **Analysis:** ABBV has consistently exceeded earnings expectations in recent quarters. The latest reported EPS of 2.65 surpassed the expected EPS of 2.57. This positive trend suggests a healthy financial performance and strong growth potential.

**5. Overall Analysis:**

ABBV has exhibited strong performance, outperforming the S&P 500 market. While the stock is currently showing signs of a potential short-term correction, its strong earnings and positive growth prospects suggest it might be a good addition to a long-term investment portfolio. However, investors should keep an eye on technical indicators and market trends for short-term trading decisions. 

**6. Recommendation:**

Considering ABBV's strong historical performance, robust earnings, and promising outlook, it might be a valuable investment opportunity for investors seeking long-term growth. It is crucial to monitor technical indicators and market trends to make informed decisions regarding short-term trading. 
